Primary Category:
Treatment Protocols
Disease Category:
Endometrial, Gynecologic
Status:
Closed
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVB or Recurrent Endometrial Cancer
Eligible for screening study DCP 001
GY018 is closed to accrual, effective December 6, 2022.
NCT#03914612
